TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07266805: Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhi

Sponsor: Pharvaris Netherlands B.V. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 48 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07266805 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07266805 Rescue Dossier →